U.S. OKs Novartis Gleevec to reduce recurring cancer

WASHINGTON (Reuters) – U.S. health regulators have approved Novartis’ drug Gleevec to reduce the risk of cancer recurring in patients with a rare type of stomach cancer, Novartis said on Friday.

CategoriesUS

Leave a Reply